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Introduction: roles of succinate beyond metabolism
The metabolite succinate or succinic acid is at the hub of the tricarboxylic acid
(TCA) cycle, and it is mainly produced by succinyl coenzyme A synthetase from
succinyl coenzyme A, in a reversible reaction that generally occurs under aerobic
conditions (Figure 1). Nonetheless, when cells rely on anaerobic glycolysis, like can-
cer cells and certain innate immune cells upon activation, other metabolic pathways
sustain succinate levels, including glutamine-dependent anerplerosis to α-ketoglu-
tarate, and eventually citrate by reductive carboxylation.1 Similarly, succinate may
derive from the γ-aminobutyric acid shunt pathway that correlates with levels of
expression of the γ-aminobutyric acid transporters solute carrier family 6 members
12 and 13 (SLC6A12, SLC6A13).2,3 Under physiological hypoxia, low oxygen levels
lead to reduced activity of succinate dehydrogenase (SDH), which metabolizes suc-
cinate, and other oxygen-dependent enzymes in the electron transport chain, caus-
ing succinate accumulation.4,5 Succinate functions as a competitive inhibitor for pro-
lyl hydroxylase domain (PHD) proteins that are central to degradation of hypoxia-
inducible factor (HIF)-1α subunit.3-6 In fact, one of the first pieces of evidence for a
role of succinate in cancer development was provided by the discovery of pseudo-
hypoxia, which refers to activation of hypoxia signaling pathways under normal
oxygen levels. Pseudohypoxia is a typical event in tumors with mutated SDH.7
Hence, succinate functions may be classified as metabolic or non-metabolic. In
mitochondria, succinate plays a crucial role in metabolism and operates in both
anabolic and catabolic pathways.2,3 Mitochondria are the physiological source for
succinate, but accumulated succinate may be transported to the cytosol through
the dicarboxylic acid translocator in the mitochondrial inner membrane and the
voltage-dependent anion channel in the outer membrane (Figure 1).6 In the cytosol,
succinate plays regulatory roles beyond primary metabolism. Elevated cytosolic
succinate levels may promote protein post-translational modifications by addition
of succinyl groups to lysine residues.8,9 A remarkable effect of succinylation is to
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alter the net charge of the protein by up to two charge
units.8,9 Further, lysine succinylation is abundant and it
induces significant structural changes in proteins,10 but its
functional effects on protein and cellular functions have
yet to be elucidated.
Interestingly, succinate connects intracellular metabolic
status and intercellular communication, as it may be
released to the extracellular space through plasma mem-
brane transporters of the SLC13 family (Figure 1).11
Nevertheless, expression of these transporters on blood
cells has not been well characterized. In the extracellular
environment, succinate contributes to intercellular signal-
ing by a receptor-mediated mechanism.12 Under steady-
state conditions, circulating levels of succinate vary from 2
to 20 mM, and pro-inflammatory stimuli such as
lipopolysaccharide (LPS), interleukin (IL)-8 and tumor
necrosis factor (TNF)-α boost its concentration.13,14 In addi-
tion, activation of succinate receptor (Figure 1) was shown
to be a critical mediator of inflammatory responses acting
in synergy with toll-like receptors (TLR), thereby enhanc-
ing TNF-α and IL-1b expression in myeloid cells.12
Succinate further functions as chemoattractant, driving
immune cell precursors from site of generation to place of
maturation.12 In humans, circulating levels of succinate
increase exponentially under certain circumstances like
endurance exercise (93 mM)15 and pathological conditions
such as type 2 diabetes (~47 to 125 mM),16,17 obesity (~80
mM),17 and ischemia-reperfusion injury following myocar-
dial infarction.18 In addition, elevated levels of circulating
succinate relate to development of solid tumors and poor
prognosis in a variety of hematologic malignancies.6,19
Conversely, activation of succinate receptor on neural stem
cells was recently shown to promote their anti-inflamma-
tory activity in an experimental model of autoimmune
encephalomyelitis.20
Here, we critically assess recent advances on the role of
succinate, beyond its metabolic functions, at the intersec-
tion between inflammatory responses and blood cell activ-
ity with the aim of identifying gaps in the literature and
proposing perspectives for further research. 
Succinylation and its potential 
immunomodulatory effects
For some time now, succinate has been known to pro-
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Figure 1. Succinate production and mechanisms of action. Succinate is an intermediate of several metabolic pathways, i.e. tricarboxylic acid (TCA) cycle under nor-
moxic conditions (blue lines), and glutamine-dependent anerplerosis and γ-aminobutyric acid (GABA) shunt under anaerobic conditions (red lines). Accumulation of
succinate associates with succinylation, i.e. addition of succinyl group to a lysine residue of a protein. Succinate inhibits action of prolyl hydroxylases (PHD) and there-
by causes stabilization of hypoxia-inducible factor-1α (HIF-1α). Succinate further inhibits several dioxygenases involved in epigenetic regulation like ten-eleven
translocation methylcytosine dioxygenase (TET) and jumonji C domain-containing histone lysine demethylases (JMJD3). Dicarboxylate carriers (DIC) and voltage-
dependent anion channels (VDAC) control succinate release from mitochondria to cytosol. Succinate is released to the extracellular space through sodium-coupled
citrate transporters (SLC13). GPR91 is a G protein–coupled cell surface receptor for extracellular succinate (Sucnr1). ACO: aconitase; IDH: isocitrate dehydrogenase;
ODC: oxoglutarate dehydrogenase; SCS: α-succinyl-CoA synthetase; SDH: succinate dehydrogenase; FUM: fumarase; MDH: malate dehydrogenase; CSY: citrate syn-
thase; GS: glutamine synthetase; GOGAT: glutamine oxoglutarate aminotransferase.
mote deoxyribonucleic acid methylation through inhibi-
tion of histone demethylases and the ten-eleven transloca-
tion family proteins (Figure 1), and thereby to play a role in
the cellular epigenetic landscape.21,22 Recently, a novel post-
translational modification was associated to succinate
accumulation that results in lysine succinylation.3,9
Succinylation implies dramatic structural changes in pro-
teins and confers a negative charge at physiological pH.9,10
Many succinylation sites on histones have been identified,
which may result in alterations in chromatin structure and,
consequently, gene expression.8,9 Mechanisms that trigger
lysine succinylation are still not clear and little is known
about its potential role in immune modulation. In
Escherichia coli, where succinylation was discovered, accu-
mulation of succinate promotes succinyl coenzyme A syn-
thetase activity, leading to higher production of succinyl
coenzyme A that acts, in turn, as succinyl donor.23 In mice,
succinylation is reverted by sirtuin 5, a member of the
nicotinamide adenine dinucleotide-dependent family of
deacetylases that exhibits desuccinylase activity.23
Succinate dehydrogenase complex mutations seem to
relate to hematopoietic malignancies, particularly lym-
phoid leukemias, in addition to endocrine cancers.19
Interestingly, human neutrophils isolated from patients
with heterozygous germ line mutations in the enzyme
SDHB, display enhanced cell survival and increased suc-
cinylation.24 However, the functional consequences of
SDHB defects for the inflammatory phenotype were not
identified, and neither was any causal mechanism found
linking SDHB mutations and succinylation of proteins in
neutrophils. Mouse models have been used to further
understand these processes, but many questions remain.
Macrophages from mice lacking SDHB accumulate succi-
nate.25 This strategy together with LPS stimulation leads to
decreased pro-inflammatory gene expression along with
enhanced expression of a variety of anti-inflammatory sol-
uble mediators, including IL-1 receptor antagonist and IL-
10.25 Accordingly, inhibition of SDH with itaconate treat-
ment, a metabolite structurally similar to succinate, abol-
ishes inflammatory response of macrophages reducing
myocardial infarct in both in vitro and in vivomodels by lim-
iting succinate oxidation.26 Thus, limiting the oxidation of
succinate may have an anti-inflammatory effect. The
prominent mechanisms mediating these effects seem to
relate to mitochondrial metabolic reprogramming and inhi-
bition of reactive oxygen species (ROS) production.25,26
Unfortunately, the potential role of succinylation in these
processes has not been studied. 
Conversely, macrophages from mice lacking sirtuin 5
become hypersensitive to LPS and display increased
expression of IL-1b.27 One important limitation of this
strategy is that it does not allow us to rule out possible
deacetylation from desuccinylation activity of sirtuin 5.
Nevertheless, the Authors elegantly showed a mechanism
that at least partially explains these results.27 Succinylation
is a modification that may occur to multiple proteins in
addition to histones. This is the case of pyruvate kinase
M2, whose succinylation at K311 promotes its transloca-
tion into the nucleus. Once in the nucleus, pyruvate kinase
M2 forms a transcriptional complex with HIF-1α that
directly binds to the IL-1b promoter gene and activates its
transcription.27 Furthermore, pyruvate kinase M2 hyper-
succinylation in sirtuin 5-deficient mice renders the ani-
mals more susceptible to experimental colitis through
boosted IL-1b production.27
Thus, future study should examine the link between suc-
cinylation and inflammatory pathways, its regulation in
different blood cell subsets, and its consequences in terms
of gene expression and immune cell functions in both
healthy and clinical conditions.
Succinate as intercellular communicator
Activation of succinate receptor 1 (SUCNR1), or G pro-
tein-coupled receptor 91 (GPR91), was recently recognized
as a regulatory mediator on a variety of cell subsets, includ-
ing cardiomyocytes, adipocytes, renal and blood cells.28-30
Half-maximal effective response for GPR91 is obtained with
succinate concentrations of 28-56 mM, indicative of GPR91
activation at succinate concentrations higher than the
steady-state levels.30 Thus, succinate-GPR91 axis may func-
tion as an early sensor of homeostasis perturbations. In this
context, selection of appropriate experimental conditions is
essential to prevent biased results. For example, use of car-
bon dioxide as a method of euthanasia in rodents should be
avoided since it rapidly raises blood succinate levels.14
G protein-coupled receptors are typically classified based
on the G protein subfamily that they activate, e.g. Gαi,
Gαq, Gs or G12/13. Given the enriched expression of
GPR91 in kidney, human embryonic kidney cells 293 are
often used to examine its mechanisms of signal transduc-
tion. However, attempts to characterize downstream path-
ways have led to controversial results. Some studies show
that GPR91 activates both Gαi and Gαq signaling, leading
to inhibition of cyclic adenosine monophosphate produc-
tion and deployment of calcium mobilization,
respectively.30 In contrast, others have shown that Gαq is
not required for succinate-induced activation of GPR91
and Gαi alone is sufficient to quench cyclic adenosine
monophosphate and mobilize calcium.29 Despite these
controversies, in vitro studies in kidney cell lines seem to
agree that GPR91 signaling is mediated by mobilization of
intracellular calcium stores rather than being dependent on
influx of extracellular calcium.29 However, stimulation of
platelets with succinate failed to induce intracellular calci-
um mobilization, indicating the potential cell type-specific
signaling transduction pathways of GPR91.29 Clues as to
the cell-wide plasticity of GPR91 can further be seen from
mesenchymal cells in the liver, where GPR91 activation
neither increases cytosolic calcium nor inhibits adenosine
monophosphate production.31
Furthermore, distinct mechanisms are responsible for
GPR91 switch off in a cell-type dependent manner. Unlike
human embryonic kidney cells 293, which undergo inter-
nalization of GPR91 in presence of succinate,32 Madin-
Darby canine kidney cells instead show a temporal desen-
sitization of GPR91 following succinate binding.32 Thus,
cell-type specific responses of GPR91 machinery and
on/off dynamics may confer great plasticity to this regula-
tory pathway and may also underlie seemingly controver-
sial results. Therefore, characterizing GPR91 signaling in
cells of interest appears to be essential to assess the impact
on functional activity and to identify specific drug targets
upon pathogenesis.
GPR91 in inflammatory responses
Early observations on blood cells show that GPR91 acti-
vation boosts pro-inflammatory responses, but recent
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investigations have shown that this is not always the case
and that the impact of GPR91 depends on the cellular con-
text. For example, GPR91 may indirectly protect mice from
low-grade systemic inflammation under high-fat-diet con-
ditions, since GPR91-deficient mice show progressive
hyperglycemia and reduced insulin secretion.33 This was
related to a function of GPR91 in white adipose tissue, a
tissue where GPR91 is highly expressed.33
Monocytes that egress from the bone marrow (BM)
seem to lack expression of GPR91, yet the ability to
respond to activation and differentiation signals is influ-
enced by extracellular succinate.12 Unlike immature mono-
cytes, both naive dendritic cells and macrophages express
high levels of GPR91, and its activation promotes inflam-
mation.12 In vitro, succinate failed to influence TNF-α and
IL-1b expression by dendritic cells. However, higher
expression of these cytokines is achieved by addition of
succinate in combination with TLR-3 and TLR-7 ligands
compared to use of TLR agonists alone.12 Macrophages
respond to extracellular inflammatory signals like LPS in
similar ways (Figure 2A), with GPR91-mediated signal
transduction yielding a strong pro-inflammatory pheno-
type that results in increased production of IL-1b.2,34
Furthermore, LPS-stimulated macrophages release succi-
nate into the cell culture  medium.34 This effect seems to be
independent of GPR91, as extracellular succinate is found
more abundantly in cultures of GPR91 deficient
macrophages than in corresponding wild-type (WT) cells.34
The underlying mechanism for this succinate transport still
needs to be revealed. In this regard, future studies examin-
ing the activity and expression of the SLC13 transporters in
blood cells will be of great interest.
In addition, GPR91 seems to be required for dendritic cell
activation and licensing in vivo. It leads dendritic cell migra-
tion to lymph nodes, as this function is impaired in GPR91-
deficient mice. However, after maturation, GPR91 expres-
sion rapidly declines, making dendritic cells unresponsive
to subsequent succinate stimulation after 24 hours of stim-
ulation with LPS or the cytokine cocktail of TNF-α and IL-
1b.12 Conversely, activated macrophages become more
responsive to succinate stimulation.12
In both human cell lines and monocyte-derived dendritic
cells, succinate activates the extracellular signal-regulated
kinases Erk1 and Erk2,12,30 which are downstream signaling
components of TLR pathways. In macrophages, HIF-1α is
one key mediator of their response to succinate.3,25
Accumulation of succinate in the cytosol results in compet-
itive inhibition of PHD enzymes and subsequent stabiliza-
tion of HIF-1α, even in the presence of normal oxygen lev-
els (Figure 2A).3,6 In turn, HIF-1α activation contributes to
IL-1b expression.3,25 Later, succinate oxidation in mitochon-
dria proved central to macrophage pro-inflammatory phe-
notype, given that competitive inhibition of SDH abro-
gates IL-1b and HIF-1α expression.25 In accordance with
the IL-1b findings previously described, HIF-1α stability is
similar in macrophages derived from both GPR91-deficient
and WT mice in presence of extracellular succinate alone,
whereas GPR91 promotes pseudohypoxia upon LPS stim-
ulation (Figure 2A).34 Recently, this mechanism has been
related to pathogenesis in an experimental model of anti-
gen-induced arthritis, where GPR91-deficient mice display
reduced macrophage activation and IL-1b production.34
Surprisingly, the inflammatory impact of GPR91 defi-
ciency varies in different myeloid cell subsets. Animal
models of allergic contact dermatitis revealed increased
reactions in the absence of GPR91, and this was related to
hyperactive mast cells in GPR91-deficient mice by means
of increased TNF-α expression.35 This effect seems to be
dependent on defective mast cell differentiation from BM
precursors, as augmented mast cell responses could be
recapitulated in WT mast cells differentiated in vitro in the
absence of succinate.35 Unfortunately, no further efforts
were made to explore the mechanisms involved.
Intriguingly, GPR91 may induce anti-inflammatory
effects through non-cell-autonomous effects (Figure 2B). In
an in vivo model of autoimmune encephalomyelitis, succi-
nate produced by type I mononuclear phagocytes accumu-
lates in the cerebrospinal fluid of the chronically inflamed
central nervous system.20 Transplanted neural stem cells
sense this extracellular succinate through GPR91. In vitro,
GPR91 activation leads neural stem cells to secretion of
prostaglandin E2, and upregulation of members of the
SLC13 family of transporters (i.e. SLC13A3 and SLC13A5)
that uptake and scavenge extracellular succinate. In vivo,
succinate scavenging seems to be the main mediator of the
anti-inflammatory effects of transplanted neural stem cells.
As a result, the beneficial effects of this strategy include
reduction of succinate levels in the cerebrospinal fluid,
shifting from type 1 inflammatory mononuclear phago-
cytes to anti-inflammatory cells, reduced post mortem tissue
pathology, and improvement of behavioral defects.20
However, GPR91 is essential for these effects in vivo, as
GPR91-deficient neural stem cells show reduced ability to
protect from chronic neuroinflammation upon transplanta-
tion.20 It remains to be seen how broadly applicable this
succinate-mediated anti-inflammatory mechanism will be
to additional regulatory cells and inflammatory disease
systems. However, it is interesting to hypothesize that suc-
cinate may play dual roles in inflammation both as an early
driver, through cell-autonomous mechanisms, and as a late
terminator by non-cell autonomous processes. Future stud-
ies should clarify the validity of this exciting hypothesis. 
In addition, given the contribution of GPR91 to tipping
the inflammatory balance, studies are required to better
understand how its modulation may provide a useful clin-
ical tool for the control of inflammatory responses and
maintenance of immune homeostasis. In this regard, recent
development of GPR91-specific agonists, up to 20-fold
more powerful compared to succinate,36 and antagonists,37
opens new avenues to explore the promising therapeutic
value of GPR91 control with any accuracy.
New insights into hematopoiesis: what role
does succinate play?
Early investigations into hematopoiesis have provided
hints of a role for succinate signaling in blood stem cell
function, i.e. blood formation or hematopoiesis. GPR91 is
expressed in monocyte-derived cell subsets, as previously
discussed, while it is absent in immature monocytes, and
T cells and B cells,38 indicative of selective roles for GPR91
on different blood cell subsets. In contrast, others have
found expression of GPR91 transcript in purified popula-
tions of blood CD14+ monocytes and platelets, whereas its
absence was confirmed in CD4+ T cells, CD8+ T cells,
CD16+ granulocytes and CD19+ B cells.39 Unexpectedly,
western blot analysis of protein expression showed pres-
ence of GPR91 in all blood cells except granulocytes.39
Interestingly, human BM CD34+ progenitor cells have been
Succinate beyond metabolism in blood
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Figure 2. Dual role for succinate as pro- and anti-inflammatory signal. (A) Succinate as pro-inflammatory signal. Toll-like receptor (TLR) activation in macrophages
causes intracellular succinate accumulation and release. In the cytosol, succinate functions as competitive inhibitor for prolyl hydroxylase domain (PHD) proteins,
promoting stabilization of hypoxia-inducible factor-1α (HIF-1α), that in turn leads to pro-inflammatory interleukin-1b (IL-1b) production.3 Activation of interleukin-1
receptor (IL-1R) increases G protein-coupled receptor 91 (GPR91) expression, and extracellular succinate interacts with GPR91. This results in pseudohypoxia and
IL-1b production, independent of HIF.34 (B) Succinate as anti-inflammatory signal. M1 inflammatory macrophages release succinate, which activates GPR91 on neu-
ral stem cells increasing the expression in vitro of prostaglandin E2 (PGE2) and members of the sodium-coupled citrate (SLC) family of transporters 13 (i.e. SLC13A3
and SLC13A5). In vivo, the most prominent anti-inflammation mechanism is succinate scavenging by SLC13 transporters. This reduces IL-1b and succinate extra-
cellular levels, and promotes a shift in macrophage polarity from pro-inflammatory (in green) to anti-inflammatory phenotype (in blue).20 LPS: lipopolysaccharide;
VHL: von Hippel-Lindau protein; Ub: ubiquitin. 
A
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reported to express GPR91 on their cell surface,38 suggest-
ing a potential role for succinate signaling in hematopoietic
stem cells (HSC). At present, the lack of commercially
available mouse GPR91-specific antibody makes it difficult
to further explore the significance of succinate-GPR91 sig-
naling pathway in the biology of HSC and progenitor cells.
In this regard, generation of reporter mouse lines will be of
great value in the hematopoietic field. 
In vitro, succinate stimulates the proliferation capacity of
erythroid and megakaryocyte progenitors, and cell prolifer-
ation is significantly hampered in cells transfected with
small interfering ribonucleic acid targeting GPR91.38
However, when megakaryocytes and erythroblasts are dif-
ferentiated in vitro from human cord blood CD34+ cells,
megakaryocytes show 7.2-fold higher GPR91 transcript
expression as detected by cDNA microarrays.39 Of note,
differentiation of CD34+ progenitors into megakaryocytes
is performed in the presence of both thrombopoietin and
IL-1b.39 As previously discussed, GPR91 signaling seems to
be required for correct mast cell differentiation.35 GPR91-
deficient mice show hypomorphic mast cells that display
increased responses, and this can be recapitulated in vitro
using WT BM cells differentiated in the absence of succi-
nate.35
Following chemotherapy, succinate treatment in vivo
stimulates multilineage blood cell recovery, including red
blood cells, platelets and neutrophils.38 In addition,
inducible deletion of the mitochondrial SDHD in mouse
models leads to remarkable hematopoietic defects, includ-
ing depletion of BM progenitors and differentiated cells,
and apoptosis in the HSC compartment defined as LSK, i.e.
lineage-negative, c-kit-positive, and sca-1-positive.40
However, the consequences of this strategy on succinate
levels in LSK cells and their link to cell functional changes
has not been studied. Furthermore, an inducible system
was used to conditionally delete SDHD controlled in a
temporal manner, using Cre mediated recombination that
activates upon estrogen analog tamoxifen administration.
However, this genetic approach does not allow the cell
subset where the deletion occurs to be delimited, either
within or outside the hematopoietic system. Given the key
role of regulatory cells within the healthy HSC niche, that
tightly controls the function, fate and numbers of HSC in
the BM,41 it may well be that these effects are partially
mediated by the stem cell niche. Future studies will be
needed to validate this exciting hypothesis. 
Interestingly, succinate is increased 24-fold in BM stro-
mal cells derived from type 2 diabetes mellitus mice com-
pared to normoglycemic mice.42 In this study, adherent
cells were used after flushing out BM cells and culture of
the adherent fraction for one week in vitro. Thus, levels of
metabolites in this study may differ from those found in
primary BM stromal cells in vivo. Furthermore, these adher-
ent cells may consist of heterogeneous populations of stro-
mal cells. Nevertheless, the Authors reveal an interesting
mechanism that may contribute to bone dysregulation in
metabolic disorders. In vitro, extracellular succinate binds to
GPR91 on osteoclastic lineage cells and stimulates osteo-
clast differentiation; a process that may contribute to the
bone resorption seen in vivo.42 Succinate may then have an
indirect effect on hematopoiesis in diabetes, as osteoclasts
function as negative regulators of HSC43 whereas
osteoblasts support lymphoid progenitors.44,45 Future stud-
ies will be required to test these ideas.
Furthermore, HIF-1α contributes importantly to cell-
cycle regulation in HSC,46 so identification of the potential
link to succinate is of high relevance. Actually, HSC reside
in hypoxic BM niches, which maintain their long-term self-
renewal by mechanisms like limiting their production of
ROS.47 This is performed through adaptation of their
metabolism to maintain a high glycolysis rate by HIF-1α
activation. These conditions change during the processes
of proliferation and differentiation, with activated cells
depending more on oxidative phosphorylation to meet the
energy requirements.47 Besides this, HSC niches are closely
related to the vasculature in the BM and have been defined
as perivascular, with mainly endothelial cells and mes-
enchymal stromal cells secreting factors that promote HSC
maintenance.48 In this regard, GPR91 has been suggested to
link capillary function to metabolic needs in other tissues,
like retina, where GPR91 is essential to establish a neovas-
cular network in response to injury through production of
numerous angiogenic factors including vascular endothelial
growth factor by retinal ganglion neurons.49 Considering
that SDH mutations, HIF-1α accumulation and elevated
levels of circulating succinate relate to pathology, particu-
larly in hematologic malignancies,6,7,16-19 characterization of
succinate signaling network, both cell- and non-cell-
autonomous, is pivotal to understand the link between
metabolic alterations that affect HSC function and hema-
tologic malignancies.
Conclusions
Succinate is an essential intermediate of the TCA cycle at
the intersection among metabolism, gene expression and
intercellular communication. Initially characterized as an
inflammatory signal, recent data show succinate-mediated
anti-inflammatory mechanisms depending on the cellular
subsets. The great plasticity of succinate biology is exempli-
fied by cell-type specific responses of GPR91 machinery
and on/off dynamics that may contribute to seemingly con-
troversial results. In this scenario, it is interesting to hypoth-
esize that succinate may play dual roles both as early driver
of inflammation, through cell-autonomous processes, and
as late terminator by intercellular communication with reg-
ulatory cells. Future studies are required to demonstrate this
idea. Furthermore, we are only starting to understand how
succinylation may influence protein activation and epige-
netic landscape, and thereby gene expression and cell func-
tion. Studies on both succinylation regulation and impact
will be highly valuable for a complete picture of succinate
biology in blood cells. Finally, early hints on hematopoiesis
seem to involve succinate in the survival and differentiation
of blood stem cells, through mechanisms that remain
unclear. Future research should carefully explore the prom-
ising therapeutic value of succinate targeting in inflamma-
tory diseases, including hematologic malignancies.50
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